Omnitrope Injection, Solution
NDC Package 0781-3001-07

11-digit billing NDC: 00781300107 · Billing unit: ML · 1.5 ML per package

Package Information

Omnitrope (somatropin) injection is  OMNITROPE is contraindicated in patients with:•Acute Critical IllnessTreatment with pharmacologic amounts of somatropin is contraindicated in patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure [see Warnings and Precautions (5.1)].•Prader-Willi Syndrome in ChildrenSomatropin is contraindicated in patients with Prader-Willi Syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. This formulation utilizes a injection, solution delivery system. Marketed by Sandoz Inc, this product is identified by NDC 0781-3001 and is authorized under FDA application BLA021426.

Identification & Billing

NDC Package Code
0781-3001-07
Package Description
1 CARTRIDGE in 1 CARTON / 1.5 mL in 1 CARTRIDGE
Product Code
11-Digit Billing Format
00781300107
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Units Per Package
1.5 ML
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Omnitrope
Non-Proprietary Name
Somatropin
Substance Name
Somatropin
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
Usage Information
 OMNITROPE is contraindicated in patients with:•Acute Critical IllnessTreatment with pharmacologic amounts of somatropin is contraindicated in patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure [see Warnings and Precautions (5.1)].•Prader-Willi Syndrome in ChildrenSomatropin is contraindicated in patients with Prader-Willi Syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients [see Warnings and Precautions (5.2)].•Active MalignancyIn general, somatropin is contraindicated in the presence of active malignancy. Any preexisting malignancy should be inactive and its treatment complete prior to instituting therapy with somatropin. Somatropin should be discontinued if there is evidence of recurrent activity. Since GHD may be an early sign of the presence of a pituitary tumor (or, rarely, other brain tumors), the presence of such tumors should be ruled out prior to initiation of treatment. Somatropin should not be used in patients with any evidence of progression or recurrence of an underlying intracranial tumor [see Warnings and Precautions (5.3)].•HypersensitivityOMNITROPE is contraindicated in patients with a known hypersensitivity to somatropin or any of its excipients. Systemic hypersensitivity reactions have been reported with postmarketing use of somatropins [see Warnings and Precautions (5.6)].•Diabetic RetinopathySomatropin is contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy.•Closed EpiphysesSomatropin should not be used for growth promotion in pediatric patients with closed epiphyses.

Regulatory & Marketing

Labeler Name
Sandoz Inc
Product Type
Human Prescription Drug
FDA Application #
BLA021426
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
05-30-2006
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

Source: PDAC
INJECTION, SOMATROPIN, 1 MG
HCPCS Dosage 1 MG
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0781-3001). Click a package code to view its specific billing and regulatory data.

5 CARTRIDGE in 1 CARTON / 1.5 mL in 1 CARTRIDGE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0781-3001-07 identifies a specific commercial package of 1 cartridge in 1 carton / 1.5 ml in 1 cartridge of Omnitrope, a human prescription drug labeled by Sandoz Inc. This injection, solution is formulated for subcutaneous use and contains somatropin as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sandoz Inc on May 30, 2006. The current certification is valid through December 31, 2027.

How is this Sandoz Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00781300107. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 1.5 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0781-3001-07
11-Digit CMS (5-4-2)
00781-3001-07

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.